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Edited by Laszlo NagyAbstract We show that transcription factor Kru¨ppel-like factor
5 (KLF5), which is important in cardiovascular remodeling,
interacts with retinoic acid receptor-alpha (RARa) to regulate
downstream gene expression. Here, we investigated whether acy-
clic retinoid (ACR) regulates KLF5 and inhibits vascular remod-
eling. Co-immunoprecipitation and pull-down binding assay
showed that ACR attenuates functional interaction of KLF5
and RARa. ACR aﬀects KLF5 functions by regulating transac-
tivation of platelet-derived growth factor A (PDGF-A) chain.
ACR may be a new vascular therapy to target KLF5 in cardio-
vascular pathology.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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We recently showed that Kru¨ppel-like transcription factor 5
(KLF5) is a mediator of stress-induced cardiovascular remod-
eling by regulating cardiac hypertrophy, atherosclerosis and
angiogenesis [1]. An intriguing ﬁnding of the study relevant
to the present study was that the actions of KLF5 could be
indirectly regulated by retinoids [1]. We found that retinoic
acid receptor-alpha (RARa) interacts with KLF5 and using
RAR agonists and antagonists that we were able to reciprocate
the cardiovascular eﬀects of KLF5 as manifested in mice deﬁ-
cient for KLF5 [1]. Brieﬂy, the retinoid agonist Am80, which
inhibited interaction of KLF5 and RARa, could attenuate vas-
cular remodeling as manifested by neointima formation similar
to eﬀects seen in KLF5-deﬁcient mice, and conversely the
RARa antagonist LE135 could augment neointima formation
[1]. A subsequent study further characterized the eﬀects of
Am80 in cardiovascular regulation namely in-stent restenosis
and further showed Am80 disrupts formation of a transcrip-
tional complex [2]. All-trans retinoic acid (ATRA), which is
a pan-RAR agonist, also harbors similar eﬀects [2]. These
studies have collectively suggested a new pathway whereby ret-*Corresponding authors. Address: Department of Cardiovascular
Medicine and Ubiquitous Preventive Medicine, Graduate School of
Medicine, The University of Tokyo, Tokyo 113-8655, Japan. Fax: +81
3 5800 8824 (T. Suzuki).
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doi:10.1016/j.febslet.2008.04.040inoids may modulate the function of a transcription factor,
KLF5, in cardiovascular remodeling with therapeutic implica-
tions. As modulation of transcription factor by small mole-
cules has remained a challenge given that this requires
penetration into the cell and further likely the nucleus where
the transcription factor exerts its function has proven to be a
diﬃcult task, modulation of function in an indirect manner
using retinoids and their receptors which can freely pass into
the cell as similar to use of steroids and nuclear receptors
may be a viable alternative.
Of the synthetic retinoids, acyclic retinoid (ACR) has a high
safety proﬁle and is presently being pursued for clinical use an
oral anti-cancer agent for hepatomas [3,4]. We have recently
shown that ACR regulates cardiovascular remodeling [5].
Brieﬂy, ACR attenuated neointimal formation by selectively
inducing retinoic acid receptor-beta (RARb), which is a pro-
apoptotic factor, in vascular cells, which results in apoptosis
of neointima cells and thus attenuates vascular remodeling
[5]. In the present study, we examined whether ACR may also
regulate interaction of KLF5 and RARa similar to other syn-
thetic retinoids which may be an alternative pathway whereby
ACR exerts its functions on cardiovascular remodeling.2. Materials and methods
2.1. Chemicals
ACR (3,7,11,15-tetramethyl-2,4,6,10,14-alltrans-hexadecapentanoic
acid) was provided by Nikken Chemical Co., and ATRA and dimethyl
sulfoxide minimum (DMSO) were purchased from Sigma (Table 1).
ATRA was dissolved in DMSO.2.2. Cell culture
Bovine aortic cells (BAECs) and NIH3T3 cells were maintained in
Dulbeccos modiﬁed Eagle medium (DMEM) (Sigma) supplemented
with 10% fetal bovine serum with 100 lg/ml streptomycin and
100 U/ml penicillin G. KLF5-3T3 and mock-3T3 cells, which were
constructed previously, were grown as described [6].2.3. Co-immunoprecipitation assay
RARa and 3xFLAG-tagged KLF5 (3xFLAG-KLF5) expression
vectors, which were previously constructed [7], were transfected into
BAECs for 24 h and incubated with ACR for another 24 h. Then,
BAECs were harvested with lysis buﬀer (50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% Triton-X, 100 lM ZnSO4, 0.5 mM
phenylmethylsulfonyl ﬂuoride, 0.5 lg/ml leupeptin, and 1 lg/ml pep-
statin). Ten microliters of anti-FLAG-M2 aﬃnity gel (Sigma) was
bound by rotating for 2 h in lysis buﬀer containing 0.5% bovine serum
albumin (BSA) (Sigma) at 4 C, then washed with FLAG wash buﬀer
(50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 100 lM ZnSO4, 0.5 mMation of European Biochemical Societies.
Table 1
Structure of ACR and ATRA
ACR
ATRA
ACR: (2E, 4E, 6E, 10E)-3,7,11,15-tetramethyl-2,4,6,10,14,-hexadecapentanoic acid.
ATRA: all-trans retinoic acid.
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statin). Immunoprecipitate was subjected to SDS–PAGE and immuno-
blotted using anti-RARa antibody (Santa Cruz).
2.4. In vitro GST pull-down binding assay
The recombinant Glutathione S-transferase (GST)-tagged RARa
(GST-RARa) construct was generated by PCR on pRS-RARa using
primers (5 0-GCCGCGAATTCATGGCCAGCAACAGCAGC-3 0 andA RAR
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Fig. 1. (A) Co-immunoprecipitation assay showing binding of RARa and KL
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tagged RARa-DNA binding domain (DBD) (GST-RARa-DBD)
construct was generated by PCR on pRS-RARa using primers
(5 0-TTGGAATTCCCCCGCATCTACAAGCCTTGC-30 and 5 0-TC
TGCAGAATTCCTTCTTCTTCTTGTTTCG-3 0) containing EcoRI
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Fig. 2. (A) Co-transfection reporter analysis of the transcriptional
eﬀects of RARa, KLF5 and ACR or ATRA on the PDGF-A promoter
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[8]. Hexahistidine-tagged constructs for KLF5-DNA binding domain
(DBD) (His-KLF5-DBD), the zinc ﬁnger peptides of KLF5, and pro-
tein expression and puriﬁcation were described previously [6]. One
micrograms of GST fusion protein was incubated with ACR or ATRA
at room temperature. After that, 10 ll of Glutathione sepharose 4B re-
sin (GE Healthcare) was added for 2 h at 4 C in binding buﬀer
(20 mM HEPES, pH 7.9, 40 mM KCl, 0.1 mM EDTA, pH 8.0). After
washing with binding buﬀer, 500 ng of each His-KLF5-DBD protein
was added and incubated for 2 h at 4 C in the same buﬀer. The bound
protein was washed three times in the same buﬀer. These proteins were
resolved by SDS–PAGE analysis and then immunoblotted with anti-
His probe (Santa Cruz) and anti-GST (Santa Cruz).
2.5. Co-transfection reporter assay
BAECs were transfected with reporter and expression plasmids by
lipofectamine 2000 (Invitrogen). Cells were incubated for 24 h and
were incubated with additive for 24 h then subjected to luciferase assay
(Promega) by luminometry (Lumat LB9507, Berthold). b-Galactosi-
dase activity was measured according to the manufacturers instruc-
tions (Promega). Shown are the results of a representative assay as
done in duplicate and reproduced in at least two other occasions. Error
bars denote S.D.
2.6. Cell count analysis
KLF5-3T3 and mock-3T3 cells were plated on 60 mm-plastic wells
(1 · 105 cells/well) at a cell density of 60–70% conﬂuency. They were
treated for 24 h in medium containing 1% FBS supplemented with
100 U/ml penicillin G and 100 lg/ml streptomycin with the indicated
concentrations of ACR, ATRA or DMSO. Cell numbers were counted
by the trypan blue dye exclusion method. To examine the growth-
inhibitory eﬀects of ACR, ATRA or DMSO, cells were treated for
24 h. Experiments were reproduced in at least three other occasions.
2.7. DNA fragmentation assay
3T3-KLF5 stable cells were treated with ACR, ATRA or DMSO (as
vehicle control) for 24 h. The cells were harvested and then apoptosis
was detected by DNA fragmentation assay using the Cell Death Detec-
tion ELIZAPLUS Kit (Roche) according to the manufacturers instruc-
tions. The assay was done in duplicate and reproduced in at least three
other occasions.
2.8. Mouse ischemic hind-limb model
Unilateral hind-limb ischemia was induced in 30-week-old male
C57BL6/N mice as described [9]. ACR and soybean oil (control) were
administered from 1 week before the procedure up to 7 days after the
procedure. Agents were administered orally with a stomach tube
(n = 10, ﬁve from the control group and ﬁve from the ACR 200 mg/
kg group). All experiments were approved by the University of Tokyo.
Hind-limb blood perfusion was measured with a laser Doppler perfu-
sion imager (LDPI) system (Moor Instruments Ltd.) as described pre-
viously [9]. In the models, LDPI was performed after surgery and then
on days 2, 4 and 7.
2.9. Statistical analysis
All data are expressed as mean values ± S.D. Statistical analysis of
the co-transfection reporter assays and DNA fragmentation assays
were analyzed by Students t-test, and of the mouse ischemic hind-limb
model experiments by ANOVA followed by Students t-test. P < 0.05
was considered statistically signiﬁcant.activity. The white bars denote controls treated without additive or
with DMSO (D) alone in lanes 1–5. The diagonal bars denote samples
treated with ATRA and the gray bars denote samples treated with
ACR in lanes 6–12. **P < 0.01. (B) Co-transfection analysis of the
transcriptional eﬀects of RARb, KLF5 and ACR or ATRA on the
PDGF-A promoter activity. The white bars denote controls treated
without additive or with DMSO (D) alone in lanes 1–5. The diagonal
bars denote samples treated with ATRA and the gray bars denote
samples treated with ACR in lanes 6–12. (C) Co-transfection analysis
of the transcriptional eﬀects of RARc, KLF5 and ACR or ATRA on
PDGF-A promoter activity. The white bars denote controls treated
without additive or with DMSO (D) alone in lanes 1–5. The diagonal
bars denote samples treated with ATRA and the gray bars denote
samples treated with ACR in lanes 6–12.3. Results
3.1. ACR inhibits interaction of KLF5 and RARa
We ﬁrst examined whether ACR aﬀects the interaction of
KLF5 and RARa by co-immunoprecipitation assay. Under
conditions which KLF5 and RARa interacted in endothelial
cells, ACR and ATRA (used as control) inhibited interaction
in a dose-dependent manner. Eﬀects of ACR were greater than
that for ATRA (Fig. 1A).As KLF5 and RARa are both zinc-ﬁnger proteins which of-
ten interact through their zinc ﬁngers, we next examined
whether the zinc-ﬁnger region of KLF5 mediates this interac-
tion and to mediate the eﬀects of ACR using GST pull-down
assay. GST pull-down assay showed that the KLF5 zinc-ﬁnger
region was suﬃcient for interaction with full-length RARa, and
that ACR attenuated interaction greater than ATRA (Fig. 1B).
Additional domain mapping showed that the zinc ﬁnger DBDs
of KLF5 and RARa were suﬃcient for interaction, but that
1758 N. Kada et al. / FEBS Letters 582 (2008) 1755–1760ACR and ATRA did not inﬂuence their interaction on GST
pull-down assay (Fig. 1C).
ACR thus attenuates interaction of KLF5 and RARa as
mediated by the formers zinc ﬁnger region in a dose-depen-
dent manner. The eﬀects of ACR were greater than for ATRA
when both were used at the same concentration.3.2. ACR attenuates the transcriptional eﬀects of KLF5 and
RARa on KLF5-downstream PDGF-A chain promoter
activity
We next examined eﬀects of ACR on transcription of a KLF
5-downstream gene, PDGF-A chain, which is regulated by
KLF5 and RARa. Under conditions in which co-transfection
of both expression vectors of KLF5 and RARa transactivated
PDGF-A chain promoter activity in endothelial cells in a
cooperative manner and under which RARa alone did not
transactivate the promoter and KLF5 only marginally, ACR
attenuated PDGF-A chain promoter activity in a dose-depen-
dent manner (Fig. 2A). These repressive eﬀects of ACR were
greater than that for ATRA (Fig. 2A). Co-transfection analy-
sis of RARb or RARc with KLF5 showed no eﬀects (Fig. 2B
and C). Thus, ACR attenuated the transactivation of KLF5
and RARa on PDGF-A chain promoter activity as regulated
by KLF5 and RARa in a selective manner.A
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Fig. 3. (A) Morphology of 3T3-stable transformants incubated in the presenc
transformants under ACR treatment for 24 h. The number of transformants
growth inhibition of 3T3-KLF5 transformants and the diagonal bar shows g
inhibition of 3T3-KLF5 stable transformants treated with ACR or ATRA fo
cultured with ACR or ATRA. Dark gray bars are ATRA- and light gray bar
fragmentation at 0 h were divided by that at 24 h. **P < 0.01.3.3. ACR inhibits the growth-stimulatory eﬀect of KLF5
To further understand eﬀects of ACR on KLF5 functions in
the cell, we next examined whether ACR might aﬀect cell
growth as regulated by KLF5. Using a stable transformant
expressing KLF5 which we previously reported to show in-
creased cell proliferation due to eﬀects of KLF5 [6], ACR
inhibited growth in a dose-dependent manner, with the eﬀect
on stable transformants being larger than on mock cells sug-
gesting involvement of selective cell growth inhibition through
eﬀects on KLF5 (Fig. 3A and B). Further, ACR inhibited
growth of the KLF5-stable transformant in a manner that
was both dose-dependent and greater than that for ATRA
(Fig. 3C). Moreover, we investigated the eﬀects of ACR on cell
apoptosis as we have recently shown that ACR induces apop-
tosis [5], which showed that ACR markedly induces apoptosis
of 3T3-KLF5 stable cells in a dose-dependent manner as com-
pared to the dose-dependent yet very marginal increases as in-
duced by ATRA (Fig. 3D). Taken together, ACR inhibits the
growth proliferative eﬀects of KLF5 at least in part through
apoptosis.
3.4. ACR inhibits angiogenesis in the acute phase of ischemia
To test functional eﬀects of ACR on angiogenesis, hind-limb
ischemia experiments in mice were done with ACR or soybean
oil (control). Blood ﬂow of the ischemic muscle treated with
R
el
at
iv
e 
ce
ll 
vi
ab
ili
ty
20
40
60
80
(-)
(M)
1
100
Cntl
(DMSO)
10-8 10-610-7
0
**
**
**
****
ACR
******(%)
D
N
A
 fr
ag
m
en
ta
tio
n 
ra
tio
0
1
2
3
4
(-fold)
** **
**
**
********
(-)
(M)
1 2 3 4 5 6
Cntl
(DMSO)
10-8 10-510-610-7
2 3 4 5
e of ACR for 24 h. (B) Growth inhibition of 3T3-KLF5 or -mock stable
treated with retinoids at 0 h was considered 100%. The white bar shows
rowth inhibition of 3T3-mock transformants. **P < 0.01. (C) Growth
r 24 h. **P < 0.01. (D) DNA fragmentation assay using 3T3-KLF5 cells
s are ACR-treated samples. The absorbance values representing DNA
A control ACR
Day 0
Day 2
Day 4
Day 7
B
0
0.2
0.4
0.6
0.8
1
1.2
1 2
Day 0
B
lo
od
 fl
ow
 ra
tio
 (L
/R
)
****
**
3
Day 2 Day 4 Day 7
4
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with control up to 7 days (Fig. 4A and B) thus indicating that
ACR impairs angiogenesis-dependent recovery from ischemia
consistent with its role to inhibit tumor angiogenesis [10].4. Discussion
Retinoids have been shown to indirectly modulate the eﬀects
of transcription factor KLF5 on vascular remodeling through
RARa [1]. Agonists and antagonists aﬀect KLF5 functions in
opposing manners and thus may be of use to diﬀerentially
modulate KLF5 actions. In addition to ATRA, the synthetic
retinoids Am80 and LE135 have been pursued to date. In
the present study, we further investigated whether ACR, which
has a high safety proﬁle and is being presently pursued for clin-
ical use [3,4] and that we have recently shown to modulate car-
diovascular remodeling per se, may also aﬀect this regulatory
pathway.
We showed that ACR attenuates the interaction of KLF5
and RARa. ACR further functionally regulated transcription
of a KLF5-downstream gene, PDGF-A chain, by attenuating
transcription of this gene promoter which is combinatorially
activated by KLF5 and RARa. Moreover, at the cellular level,
ACR attenuated growth stimulatory eﬀects of KLF5 at least inpart through apoptosis. Therefore, ACR modulated KLF5
activities in a functional manner.
Modulation of transcription factor function through indirect
modulation of interacting partners or complex formation is
relatively new both as a molecular mechanism but even more
as a therapeutic pathway. Zinc-ﬁnger proteins are known to
interact often through their zinc-ﬁnger regions, and as ex-
pected, KLF5 and RARa interacted through these regions
[11]. As the ligand-binding domain of RARa is separate from
the zinc-ﬁnger region of RARa [12], and as the interaction of
the DNA-binding domain of RARa lacking its ligand binding
domain with KLF5 was not aﬀected by ligand, we believe that
ACR by binding the ligand-binding domain induces an alloste-
ric eﬀect on the zinc-ﬁnger domain thus aﬀecting interaction
with its interactor, in this case being KLF5. Modulation of
KLF5 functions or any other transcription factor using small
molecules is diﬃcult given that they must penetrate the cell
and nucleus to exert functions on transcription. Regulation
of expression by gene silencing (e.g. RNA interference) has
proven to be the most potent means to regulate molecular
function which is a commonly used method [13], but RNA
interference has limitations as it is still not readily applicable
at the tissue and animal level as compared to successful exper-
imental use at the cellular level. Translation of RNA interfer-
ence technology to the clinic has therefore been limited to use
in ocular disease (e.g. macular degeneration) and cancer
requiring direct injection into cells [14,15]. Thus, indirect mod-
ulation through regulation of interactor is a viable means for
therapeutic intervention at present. Although we have shown
that KLF5 actions can be modulated by retinoids, other com-
binations through diﬀerent interactors will surely be possible.
Mechanistically, nuclear receptors have been well docu-
mented to show regulation of transcriptional complex forma-
tion by ligand with interchange of co-repressors by co-
activator proteins and complexes [16]. Interaction between nu-
clear receptor and zinc-ﬁnger transcription factor has also been
documented as described for interaction of Sp1 with nuclear
receptor [17]. A related protein, Kru¨ppel-like transcription fac-
tor 9 (KLF9), has further been shown to interact with proges-
terone receptor-A (PR-A) [18]. Our present knowledge of
interaction pathways is still relatively limited, but once we have
a comprehensive understanding of protein–protein interac-
tions and their regulation, especially by ligand and other path-
ophysiologic conditions, we should be able to better target
speciﬁc pathways in a selective manner. Further crystallo-
graphic studies will also help us better understand the mecha-
nistic basis underlying interaction and their regulation.
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